Experimental and clinical data revealed that passively administered IgG antibodies engage Fc receptors on DCs to stimulate a long-lasting anti-tumor cellular immune response (51), what is termed as “vaccinal effect.” Upon IgG immune complex binding, DCs undergo maturation and enhance CD8+ T-cell adaptive immunity through their antigen presentation function, as well as prime a TH1 CD4+ T-cell response (51, 52). The gene discussed is CD8A; the disease is neoplasm.